Skip to main content

Advertisement

Table 3 Ongoing phase 3 trials on nonanti-amyloid therapy in AD in 2019

From: Clinical trials of new drugs for Alzheimer disease

AgentMechanism of actionTarget type and therapeutic purposeNCT numberStatus
AC-1204Induction of ketosisMetabolic; symptomatic cognitive enhancerNCT01741194Completed
AGB101 (levetiracetam)SV2A modulatorAmyloid-related and neuroprotective; disease-modifying therapyNCT03486938Recruiting
AripiprazolePartial agonist at dopamine D2 and 5-HT 1A receptorsNeurotransmitter based; symptomatic cognitive enhancerNCT02168920Terminated
AVP-786Sigma-1 receptor agonist, NMDA receptor antagonistNeurotransmitter based; BPSD (agitation)NCT03393520Recruiting
   NCT02446132Recruiting
   NCT02442765Completed
   NCT02442778Completed
AXS-05Sigma-1 receptor agonist; NMDA receptor antagonist and dopamine-norepinephrine reuptake inhibitorNeurotransmitter based; BPSD (agitation)NCT03226522Recruiting
AzeliragonMicroglial activation inhibitor, antagonist of the receptor for advanced glycation end productsAmyloid-related and antineuroinflammatory; disease modifying therapyNCT02916056Terminated
   NCT02080364Terminated
   NCT03980730Recruiting
OPC-34712 (brexpiprazole)A partial agonist at serotonin 5-hydroxytryptamine1A and dopamine D2 receptors and an antagonist at serotonin 5-hydroxytryptamine2ANeurotransmitter based; BPSD (agitation)NCT01922258Completed
   NCT01862640Completed
   NCT03620981Recruiting
   NCT03548584Recruiting
   NCT03594123Recruiting
   NCT03724942Recruiting
Coconut oilReduction in ADP-ribosylation factor
1 protein expression
Anti-amyloid, antineuroinflammatory, anti-oxidative, and neuroprotective; symptomatic cognitive enhancerNCT01883648Terminated
COR388Bacterial protease inhibitorAntineuroinflammatory; disease-modifying therapyNCT03823404Recruiting
EscitalopramSerotonin reuptake inhibitionNeurotransmitter based; BPSD (agitation)NCT03108846Recruiting
Gabapentin EnacarbilGlutamate receptor-independent mechanismsNeurotransmitter based and neuroprotective; symptomatic cognitive enhancerNCT03082755Recruiting
Ginkgo bilobaAntioxidant and anti-amyloid aggregationAntioxidant and anti-amyloid; symptomatic cognitive enhancerNCT03090516Recruiting
GuanfacineAlpha-2A-adrenoceptor agonist, a potent 5-HT2B receptor agonistNeurotransmitter based; symptomatic cognitive enhancerNCT03116126Recruiting
Icosapent ethyl (IPE)Omega-3 fatty acids protect neurons from diseaseNeuroprotective; disease-modifying therapyNCT02719327Recruiting
Idalopirdine5-HT6 receptor antagonistNeurotransmitter based; symptomatic cognitive enhancerNCT02006641Completed
   NCT01955161Completed
   NCT02006654Completed
   NCT02079246Completed
RVT-101 (intepirdine)5-HT6 receptor antagonistNeurotransmitter based; symptomatic cognitive enhancerNCT02586909Terminated
   NCT02585934Completed
Insulin (Humulin® R U-100)MetabolicMetabolic; symptomatic cognitive enhancerNCT01767909Completed
ITI-007 (lumateperone)A potent 5-HT2A antagonistNeurotransmitter based; symptomatic cognitive enhancerNCT02817906Terminated
Losartan, amlodipine, aerobic exercise training, and othersAngiotensin II receptor blocker, calcium channel blocker, cholesterol agentAntineuroinflammatory and metabolic; symptomatic cognitive enhancerNCT02913664Recruiting
MasitinibSelective tyrosine kinase inhibitorAntineuroinflammatory; disease modifying therapyNCT01872598Active, not recruiting
MethylphenidateDopamine reuptake inhibitorNeurotransmitter based; BPSD (apathy)NCT03811847Recruiting
   NCT02346201Recruiting
MirtazapineAlpha-1 antagonistNeurotransmitter based; BPSD (agitation)NCT03031184Recruiting
MK-4305 (suvorexant)Orexin antagonistBPSD (sleep)NCT02750306Completed
EVP-6124Selective α7 nicotinic acetylcholine receptor partial agonistCholinergic system; symptomatic cognitive enhancerNCT02004392Terminated
   NCT01969136Terminated
   NCT01969123Terminated
NabiloneAgonists at cannabinoid receptors 1 and 2 (CB1/2)Neurotransmitter based; BPSD (agitation)NCT02351882Completed
NilvadipineDihydropyridine calcium channel blockerAmyloid-related, neuroprotective, and antineuroinflammatory; disease-modifying therapyNCT02017340Completed
AVP-923 (nuedexta)Uncompetitive NMDA glutamate receptor antagonist, a sigma-1 receptor agonist, and a serotonin and norepinephrine reuptake inhibitorNeurotransmitter based and neuroprotective; symptomatic cognitive enhancerNCT01832350Unknown
PioglitazonePeroxisome proliferator-activated receptor gamma (PPAR-γ) agonistsAntineuroinflammatory and neuroprotective; symptomatic cognitive enhancersNCT02284906Terminated
   NCT01931566Terminated
TroriluzoleGlutamate modulatorNeuroprotective; disease modifying therapyNCT03605667Recruiting
TRx0237 (LMTX)Tau stabilizers and aggregation inhibitorsAnti-tau; disease-modifying therapyNCT01689233Completed
   NCT02245568Terminated
   NCT03446001Recruiting
Vitamin D3 (cholecalciferol)Agonist of vitamin D receptor and other membrane-based receptors such as MARRSMetabolic; symptomatic cognitive enhancerNCT01409694Completed
Zolpidem ZopliconeAllosteric modulator of GABA-A receptorsNeurotransmitter based; BPSD (sleep)NCT03075241Recruiting
  1. BPSD = behavioral psychological symptoms of dementia; NMDA = N-methyl-D-aspartate